BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31846689)

  • 21. Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.
    Wang T; Abou-Ouf H; Hegazy SA; Alshalalfa M; Stoletov K; Lewis J; Donnelly B; Bismar TA
    J Mol Med (Berl); 2016 Dec; 94(12):1411-1422. PubMed ID: 27534968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
    Tian H; Chou FJ; Tian J; Zhang Y; You B; Huang CP; Yeh S; Niu Y; Chang C
    J Exp Clin Cancer Res; 2021 Jan; 40(1):3. PubMed ID: 33390173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.
    Duan W; Qian W; Zhou C; Cao J; Qin T; Xiao Y; Cheng L; Li J; Chen K; Li X; Ma J; Ma Q
    Oncol Rep; 2018 Sep; 40(3):1495-1502. PubMed ID: 29956804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer.
    Gonthier K; Poluri RTK; Weidmann C; Tadros M; Audet-Walsh É
    Mol Cancer Res; 2019 Aug; 17(8):1699-1709. PubMed ID: 31068457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).
    Bonaccorsi L; Carloni V; Muratori M; Formigli L; Zecchi S; Forti G; Baldi E
    Int J Cancer; 2004 Oct; 112(1):78-86. PubMed ID: 15305378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor is a tumor suppressor and proliferator in prostate cancer.
    Niu Y; Altuwaijri S; Lai KP; Wu CT; Ricke WA; Messing EM; Yao J; Yeh S; Chang C
    Proc Natl Acad Sci U S A; 2008 Aug; 105(34):12182-7. PubMed ID: 18723679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
    Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ
    PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals.
    Luo J; Lee SO; Cui Y; Yang R; Li L; Chang C
    Oncotarget; 2015 Sep; 6(29):27555-65. PubMed ID: 26342197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells.
    Gerdes MJ; Dang TD; Larsen M; Rowley DR
    Endocrinology; 1998 Aug; 139(8):3569-77. PubMed ID: 9681509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial cells promote metastasis of prostate cancer by enhancing autophagy.
    Zhao R; Bei X; Yang B; Wang X; Jiang C; Shi F; Wang X; Zhu Y; Jing Y; Han B; Xia S; Jiang Q
    J Exp Clin Cancer Res; 2018 Sep; 37(1):221. PubMed ID: 30200999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor and invasion in prostate cancer.
    Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
    Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer.
    Tang Y; Wu B; Huang S; Peng X; Li X; Huang X; Zhou W; Xie P; He P
    Oncol Rep; 2019 Jan; 41(1):57-66. PubMed ID: 30365141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells.
    Yu L; Wang CY; Shi J; Miao L; Du X; Mayer D; Zhang J
    Endocrinology; 2011 Mar; 152(3):773-81. PubMed ID: 21248144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasion.
    Gang X; Wang G; Huang H
    Prostate; 2015 May; 75(6):561-72. PubMed ID: 25631036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines.
    Diallo JS; Péant B; Lessard L; Delvoye N; Le Page C; Mes-Masson AM; Saad F
    Prostate; 2006 Sep; 66(12):1245-56. PubMed ID: 16705740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
    Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
    Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel role of Giα2 in cell migration: Downstream of PI3-kinase-AKT and Rac1 in prostate cancer cells.
    Caggia S; Chunduri H; Millena AC; Perkins JN; Venugopal SV; Vo BT; Li C; Tu Y; Khan SA
    J Cell Physiol; 2018 Jan; 234(1):802-815. PubMed ID: 30078221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.